welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program
study id #: NCT02747862
condition: Attenuated Familial Adenomatous Polyposis, Deleterious Familial Adenomatous Polyposis
status: recruiting, registry/observationalpurpose:
The primary objective of this chart review study is to evaluate the outcomes of subjects with Attenuated Familial Adenomatous Polyposis (AFAP) and Deleterious Familial Adenomatous Polyposis (FAP) who have not undergone surgical resection of the colon. A secondary objective of this study is to compare 1) the colonoscopic and pathology histories including history of ampullary adenoma in the duodenum over family generations, 2) the use of chemopreventive medications, and 3) clinical features of subjects who pursued prophylactic surgical resection of the colon with those that have elected to continue routine colonoscopic surveillance in an effort to better characterize factors (e.g. polyp burden, ampullary adenoma and level of dysplasia, etc) which may influence management decisions.
intervention: Other: Chart Review
start date: February 2008
estimated completion: February 2020
last updated: May 23, 2019
size / enrollment: 1500
Observational Model: Cohort
Time Perspective: Retrospective
The UTMDACC family history database will be queried for the presence of cases meeting the above criteria (attenuated Familial Adenomatous Polyposis (FAP), classical AFP [i.e. identifiable APC mutation], and/or a compatible family history or personal adenoma burden of > 50 adenomas).
The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery will be collected through chart review and all data is retrospective as of February 15, 2016.
The University of Texas MD Anderson Cancer Center (UTMDACC) medical record number for these cases will be used to identify the patient in ClinicStation: 1) records of endoscopy procedures, 2) operative reports, and 3) associated clinic notes will be reviewed for: a) whether the above evaluation criteria have been met, b) age, c) gender, d) age at initial colonoscopy, e) total number of colonoscopies, f) number of adenomas identified, g) cancer diagnoses, h) chemopreventive medications, i) type of surgery, j) number of hospitalizations, k) length of hospital stay, l) identification of an underlying APC mutation, and ll) family history information. The UT MDACC family history database will also be reviewed for updated family history information including ampullary adenomas and outcomes of genetic testing for identified cases.
- Chart Review of Outcomes of Participants with Attenuated Familial Adenomatous Polyposis (AFAP) and Deleterious Familial Adenomatous Polyposis (FAP) Undergoing Endoscopic Surveillance [ Time Frame: 12 years ] [ Designated as safety issue: No ]
For comparisons between groups, the Mann-Whitney test used.
• Eligible Sexes: all
exclusion criteria: Participants who do not have with Attenuated Familial Adenomatous Polyposis (AFAP) and Deleterious Familial Adenomatous Polyposis (FAP).
expertly curated content related to this topic
- Body Image, Cosmesis, Quality of Life, and Functional Outcome of Hand-Assisted Laparoscopic Versus Open Restorative ...BACKGROUND : This study aimed to compare...
- Chemoprevention of Colorectal Cancer: Systematic Review and Economic EvaluationBACKGROUND : Colorectal cancer (CRC) is ...
- Stages and Evaluation of Surgical Innovation: A Clinical Example of the Ileo Neo Rectal Anastomosis After Ulcerative...AIM: So far, not many clinical examples...
- Sulindac Sulfone Induced Regression of Rectal Polyps in Patients with Familial Adenomatous PolyposisSulindac sulfone (Exisulind), a metaboli...
- Guide to Fighting Colon Polyps: How to Prevent Colon Polyps Naturally With FoodFrom garlic and turmeric to foods that c...
- Dietary Polyamine Intake and Risk of Colorectal Adenomatous PolypsBACKGROUND : Putrescine, spermidine, and...
- A Prospective Multicenter Phase II Study of Sunitinib in Patients With Advanced Aggressive FibromatosisSeveral studies have reported that imati...